The use of PET/CT in prostate cancer

Li, Roger; Ravizzini, Gregory; Gorin, Michael A.; Maurer, Tobias; Eiber, Matthias; Cooperberg, Matthew R.; Alemozzaffar, Mehrdad; Tollefson, Matthew K.; Delacroix, Scott E.; Chapin, Brian F.

doi:10.1038/s41391-017-0007-8

Cited by 81 publications

(58 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET/CT recently emerged as a promising diagnostic imaging platform for both primary and recurrent prostate cancers [26]. In addition to 18 F-FDG, routine clinical imaging procedures use various radiolabelled tracers [e.g., 18 F-choline, 18 F-NaF, 68 Ga-prostate-specific membrane antigen (PSMA), 68 Ga-DOTATATE, 18 F-FACBC] with demonstrated efficacy for cancer diagnosis in various clinical settings [26][27]. Newly developed tracers exhibit increased accuracy for the detection of small, incipient metastatic foci [28][29].…”

Section: Discussionmentioning

confidence: 99%

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Luo

Ruan

Pang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Biopsy is considered the gold-standard technique for prostate cancer diagnosis and is recommended in patients with a high clinical indication of prostate cancer. In this study, we aimed to determine the diagnostic efficacy of a novel positron emission tomography (PET)/computed tomography (CT)-guided percutaneous trans-pararectal space-based approach to targeted prostate biopsy.Methods PET/CT-guided percutaneous trans-pararectal space prostate biopsies were performed in 14 consecutive patients with indications of prostate cancer. Whole-body 18 F-FDG PET/CT indicated the presence of 18 F-fluorodeoxyglucose (FDG)-avid focal prostate lesions. Two tissue specimens were obtained from each patient. The final diagnoses were established based on the results of a histopathological analysis and clinical follow-up, and these findings were used to verify the diagnostic accuracy of 18 F-FDG PET/CT for prostate cancer.Results The diagnostic accuracy of 18 F-FDG PET/CT for prostate cancer was 81.8%. Further analyses of the two biopsied samples per patient led to confirmed histopathological and immunohistochemical diagnoses of prostate cancer in all 14 patients. Consequently, the success rate of PET/CT-guided percutaneous trans-pararectal space prostate-targeted biopsy for the diagnosis of prostate cancer was 100.0% (14/14). Regarding safety, the average duration of biopsy was 20 min, and no serious complications occurred.Conclusions PET/CT-guided percutaneous trans-pararectal space prostate biopsy may yield a new approach to targeted prostate biopsy for the diagnosis of prostate cancer. Moreover, this biopsy procedure can be performed safely without complications, and is more cost-effective than conventional trans-rectal and trans-perineal prostate biopsy methods.

show abstract

Section: Discussionmentioning

confidence: 99%

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Luo

Ruan

Pang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Improvements in cancer care have been linked closely to advances in imaging technologies, as these improvements enable a more accurate diagnosis, staging, and surveillance of disease. PET/CT recently emerged as a promising diagnostic imaging platform for both primary and recurrent prostate cancers [26]. In addition to 18 F-FDG, routine clinical imaging procedures use various radiolabelled tracers [e.g., 18 F-choline, 18 F-NaF, 68 Ga-prostate-specific membrane antigen (PSMA), 68 Ga-DOTATATE, 18 F-FACBC] with demonstrated efficacy for cancer diagnosis in various clinical settings [26][27].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Luo

Ruan

Pang

et al. 2019

Preprint

View full text Add to dashboard Cite

Oncology 2 KEYWORDS positron emission tomography/computed tomography, prostate cancer, percutaneous trans-pararectal space prostate biopsy Abstract Background: Biopsy is considered the gold-standard technique for prostate cancer diagnosis and is recommended in patients with a high clinical indication of prostate cancer. In this study, we aimed to determine the diagnostic efficacy of a novel positron emission tomography (PET)/computed tomography (CT)-guided percutaneous trans-pararectal space-based approach to targeted prostate biopsy. Methods: PET/CT-guided percutaneous trans-pararectal space prostate biopsies were performed in 14 consecutive patients with indications of prostate cancer. Whole-body 18F-FDG PET/CT indicated the presence of 18F-fluorodeoxyglucose (FDG)-avid focal prostate lesions. Two tissue specimens were obtained from each patient. The final diagnoses were established based on the results of a histopathological analysis and clinical follow-up, and these findings were used to verify the diagnostic accuracy of 18F-FDG PET/CT for prostate cancer. Results: The diagnostic accuracy of 18F-FDG PET/CT for prostate cancer was 81.8%. Further analyses of the two biopsied samples per patient led to confirmed histopathological and immunohistochemical diagnoses of prostate cancer in all 14 patients. Consequently, the success rate of PET/CT-guided percutaneous trans-pararectal space prostate-targeted biopsy for the diagnosis of prostate cancer was 100.0% (14/14). Regarding safety, the average duration of biopsy was 20 min, and no serious complications occurred.Conclusions: PET/CT-guided percutaneous trans-pararectal space prostate biopsy may yield a new approach to targeted prostate biopsy for the diagnosis of prostate cancer. Moreover, this biopsy procedure can be performed safely without complications, and is more cost-effective than conventional trans-rectal and trans-perineal prostate biopsy methods.

show abstract

“…When PSA is high (>10 ng/mL), standard imaging i.e., CT scan and bone scan is usually sufficient to confirm the metastatic status (63). However, in cases of BCR and a low PSA level, PET/CT may be indicated to view the recurrence site and search for distant metastases with more accuracy than conventional imaging (39,65).…”

Section: Is There Bone Disease?mentioning

confidence: 99%

Imaging for Metastasis in Prostate Cancer: A Review of the Literature

et al. 2020

View full text Add to dashboard Cite

Background: Initial staging and assessment of treatment activity in metastatic prostate cancer (PCa) patients is controversial. Indications for the various available imaging modalities are not well-established due to rapid advancements in imaging and treatment. Methods:We conducted a critical literature review of the main imaging abnormalities that suggest a diagnosis of metastasis in localized and locally advanced PCa or in cases of biological relapse. We also assessed the role of the various imaging modalities available in routine clinical practice for the detection of metastases and response to treatment in metastatic PCa patients. Results:In published clinical trials, the most commonly used imaging modalities for the detection and evaluation of therapeutic response are bone scan, abdominopelvic computed tomography (CT), and pelvic and bone magnetic resonance imaging (MRI). For the detection and follow-up of metastases during treatment, modern imaging techniques i.e., choline-positron emission tomography (PET), fluciclovine-PET, or Prostate-specific membrane antigen (PSMA)-PET provide better sensitivity and specificity. This is particularly the case of fluciclovine-PET and PSMA-PET in cases of biochemical recurrence with low values of prostate specific antigen. Conclusions:In routine clinical practice, conventional imaging still have a role, and communication between imagers and clinicians should be encouraged. Present and future clinical trials should use modern imaging methods to clarify their usage. Inclusion and Exclusion CriteriaOnly original manuscripts and reviews published in indexed and peer-reviewed journals and written in English between August 1999 and December 2019 were considered. Cross-sectional studies, case reports, published abstracts, dissertation materials, and conference presentations were excluded. Of 1,725 potential articles from the literature search, 105 were selected, including 16 literature reviews, 5 meta-analyses, 11 guidelines or position papers, and 73 original articles.

show abstract

The use of PET/CT in prostate cancer

Cited by 81 publications

References 148 publications

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Imaging for Metastasis in Prostate Cancer: A Review of the Literature

Contact Info

Product

Resources

About